SBFM Sunshine Biopharma Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
14:20
Sep 16
Sep 16
Generic drug growth plus mRNA pipeline at ~$1
The author notes SBFM did $36.3m in revenue in 2025 and launched 9 generic drugs, with additional Canadian approvals (ondansetron, dienogest, enalapril, atenolol) and amoxicillin already moving into pharmacy shipments. The bull case is that the growing generic business starts showing up more clearly in the numbers while the early-stage biotech side (K1.1 mRNA tumor suppression in mouse liver cancer models, coronavirus candidate in IND-enabling studies) keeps advancing. Stated risks include a $5.98m loss last year, financing, dilution and reverse split history. No explicit time horizon given.
HIGH
14:01
Jan 21
Jan 21
Canadian ops make SBFM tariff-immune acquisition target
The author claims Sunshine Biopharma is immune to US-EU conflict because its core operations are in Canada, positioning it on neutral territory. Looming tariffs and counter-tariffs could push Big Pharma to acquire companies on neutral ground, making SBFM a potential takeover target. The author also notes the company is well-positioned in the generic drug market with steadily growing revenues. No specific timeframe or risk is stated.
MED
About SBFM Investor Commentary
Across the available history and selected sources, Buzzberg tracks SBFM (Sunshine Biopharma Inc.) across 2 sources: 1 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 50% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 2 total trade ideas tracked. Past 7 days, before deduplication: 1 other directions. Latest voices: u/thebullwire, u/neverbackdowm.